Cisplatin, dacarbazine, and fotemustine plus interferon α in patients with advanced malignant melanoma: A multicenter Phase II study of the Southern Italy …
A Daponte, PA Ascierto, A Gravina, MT Melucci… - Cancer, 2000 - Wiley Online Library
BACKGROUND In a previous study, the authors tested the combination of fotemustine (FM)
100 mg/m2 intravenously (iv) on Day 1, dacarbazine (DTIC) 250 mg/m2 iv on Days 2–5, and …
100 mg/m2 intravenously (iv) on Day 1, dacarbazine (DTIC) 250 mg/m2 iv on Days 2–5, and …
Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative …
A Daponte, PA Ascierto, A Gravina, MT Melucci… - Cancer, 2000 - europepmc.org
Background In a previous study, the authors tested the combination of fotemustine (FM) 100
mg/m (2) intravenously (iv) on Day 1, dacarbazine (DTIC) 250 mg/m (2) iv on Days 2-5, and …
mg/m (2) intravenously (iv) on Day 1, dacarbazine (DTIC) 250 mg/m (2) iv on Days 2-5, and …
[引用][C] Cisplatin, dacarbazine, and fotemustine plus interferon a in patients with advanced malignant melanoma: A multicenter Phase II study of the Southern Italy …
A DAPONTE, PA ASCIERTO, A GRAVINA… - Cancer, 2000 - pascal-francis.inist.fr
Cisplatin, dacarbazine, and fotemustine plus interferon a in patients with advanced malignant
melanoma: A multicenter Phase II study of the Southern Italy Cooperative Oncology Group …
melanoma: A multicenter Phase II study of the Southern Italy Cooperative Oncology Group …
[PDF][PDF] Cisplatin, Dacarbazine, and Fotemustine plus Interferon in Patients with Advanced Malignant Melanoma
A Daponte, PA Ascierto, A Gravina, MT Melucci… - 2000 - academia.edu
BACKGROUND. In a previous study, the authors tested the combination of fotemustine (FM)
100 mg/m2 intravenously (iv) on Day 1, dacarbazine (DTIC) 250 mg/m2 iv on Days 2–5, and …
100 mg/m2 intravenously (iv) on Day 1, dacarbazine (DTIC) 250 mg/m2 iv on Days 2–5, and …
Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative …
A Daponte, PA Ascierto, A Gravina, MT Melucci… - Cancer, 2000 - pubmed.ncbi.nlm.nih.gov
Background In a previous study, the authors tested the combination of fotemustine (FM) 100
mg/m (2) intravenously (iv) on Day 1, dacarbazine (DTIC) 250 mg/m (2) iv on Days 2-5, and …
mg/m (2) intravenously (iv) on Day 1, dacarbazine (DTIC) 250 mg/m (2) iv on Days 2-5, and …